olaparib
astrazeneca,merck
['1357o', 'propel', 'olaparib', 'prostate', 'brca', 'crpc']
the #oncoalerttoptweet day 2 #esmo22
tweet abs# 1357o: updated results from the phase iii propel trial showed rpfs benefit of using aap + olaparib in non-hrrm, hrrm, &amp; brcam status; hr 0.76, 0.50, and 0.23, respectively in mcrpc #prostatecance best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??